Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
RBC Capital Markets to hold a virtual conference » 09:52
05/17/21
05/17
09:52
05/17/21
09:52
AEGXF

Aecon Group

$15.20 /

+0.34 (+2.29%)

, BYDGF

Boyd Group Services

$176.83 /

-5.51677 (-3.03%)

, CNI

Canadian National

$107.47 /

+0.05 (+0.05%)

, CP

Canadian Pacific

$79.99 /

+0.07 (+0.09%)

, GBT

Global Blood Therapeutics

$36.19 /

+ (+0.00%)

, GDRX

GoodRx

$30.08 /

-0.91 (-2.94%)

, GILD

Gilead

$68.98 /

+0.43 (+0.63%)

, IONS

Ionis Pharmaceuticals

$38.15 /

-0.09 (-0.24%)

, MRETF

Martinrea

$11.06 /

+0.27 (+2.50%)

Automotive, Industrials…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRETF Martinrea
$11.06 /

+0.27 (+2.50%)

IONS Ionis Pharmaceuticals
$38.15 /

-0.09 (-0.24%)

GILD Gilead
$68.98 /

+0.43 (+0.63%)

GDRX GoodRx
$30.08 /

-0.91 (-2.94%)

GBT Global Blood Therapeutics
$36.19 /

+ (+0.00%)

CNI Canadian National
$107.47 /

+0.05 (+0.05%)

AEGXF Aecon Group
$15.20 /

+0.34 (+2.29%)

AEGXF Aecon Group
$15.20 /

+0.34 (+2.29%)

04/26/21 BMO Capital
Aecon Group price target lowered to C$19 from C$20 at BMO Capital
04/26/21 Canaccord
Aecon Group price target raised to C$23 from C$21 at Canaccord
03/02/21 Desjardins
Aecon Group price target raised to C$23 from C$20 at Desjardins
03/02/21 TD Securities
Aecon Group price target raised to C$22 from C$19 at TD Securities
BYDGF Boyd Group Services
$176.83 /

-5.51677 (-3.03%)

05/13/21 CIBC
Boyd Group Services price target lowered to C$260 from C$275 at CIBC
05/13/21 BMO Capital
Boyd Group Services price target lowered to C$248 from C$263 at BMO Capital
05/13/21 Stifel
Boyd Group Services price target lowered to C$240 from C$250 at Stifel
05/13/21 National Bank
Boyd Group Services price target lowered to C$260 from C$265 at National Bank
CNI Canadian National
$107.47 /

+0.05 (+0.05%)

05/14/21 Stephens
Canadian rail that loses KCS likely to pursue an Eastern rail, says Stephens
05/14/21 Citi
Citi sees Canadian National, Kansas City Southern deal as most likely outcome
04/27/21 CIBC
Canadian National price target lowered to C$146 from C$148 at CIBC
04/27/21 Wells Fargo
Canadian National price target raised to $120 from $113 at Wells Fargo
CP Canadian Pacific
$79.99 /

+0.07 (+0.09%)

04/26/21 Deutsche Bank
Canadian Pacific price target raised to $405 from $368 at Deutsche Bank
04/26/21 Susquehanna
Canadian Pacific will have to raise bid to win KSU war, says Susquehanna
GBT Global Blood Therapeutics
$36.19 /

+ (+0.00%)

05/07/21 Cantor Fitzgerald
Global Blood Therapeutics price target lowered to $110 from $120 at Cantor Fitzgerald
05/06/21 Piper Sandler
Global Blood price target lowered to $45 from $50 at Piper Sandler
04/14/21
Fly Intel: Top five analyst initiations
04/14/21 SVB Leerink
SVB Leerink bullish on Global Blood Therapeutics, initiates with an Outperform
GDRX GoodRx
$30.08 /

-0.91 (-2.94%)

05/14/21 RBC Capital
GoodRx price target lowered to $50 from $56 at RBC Capital
05/14/21 Barclays
GoodRx price target lowered to $33 from $43 at Barclays
05/14/21 Citi
GoodRx price target lowered to $53 from $70 at Citi
05/12/21 SVB Leerink
GoodRx moat still intact as Amazon Pharmacy push continues, says SVB Leerink
GILD Gilead
$68.98 /

+0.43 (+0.63%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
IONS Ionis Pharmaceuticals
$38.15 /

-0.09 (-0.24%)

05/07/21 UBS
Ionis Pharmaceuticals upgraded to Neutral from Sell at UBS
03/29/21 Piper Sandler
Ionis' Phase 2 data for PKK-LRx 'impressive' at face value, says Piper Sandler
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/23/21 Truist
Truist sees mixed readthroughs to Wave's toplines from competitor HD setback
MRETF Martinrea
$11.06 /

+0.27 (+2.50%)

04/30/21 TD Securities
Martinrea price target lowered to C$18 from C$18.50 at TD Securities
03/05/21 BMO Capital
Martinrea price target raised to C$17 from C$16 at BMO Capital
03/05/21 Scotiabank
Martinrea price target lowered to C$18.50 from C$19.50 at Scotiabank
03/05/21 TD Securities
Martinrea downgraded to Hold from Buy at TD Securities
IONS Ionis Pharmaceuticals
$38.15 /

-0.09 (-0.24%)

GILD Gilead
$68.98 /

+0.43 (+0.63%)

GDRX GoodRx
$30.08 /

-0.91 (-2.94%)

GBT Global Blood Therapeutics
$36.19 /

+ (+0.00%)

CP Canadian Pacific
$79.99 /

+0.07 (+0.09%)

CNI Canadian National
$107.47 /

+0.05 (+0.05%)

  • 23
    Sep
GILD Gilead
$68.98 /

+0.43 (+0.63%)

GDRX GoodRx
$30.08 /

-0.91 (-2.94%)

CP Canadian Pacific
$79.99 /

+0.07 (+0.09%)

CNI Canadian National
$107.47 /

+0.05 (+0.05%)

IONS Ionis Pharmaceuticals
$38.15 /

-0.09 (-0.24%)

GILD Gilead
$68.98 /

+0.43 (+0.63%)

GDRX GoodRx
$30.08 /

-0.91 (-2.94%)

GBT Global Blood Therapeutics
$36.19 /

+ (+0.00%)

CNI Canadian National
$107.47 /

+0.05 (+0.05%)

IONS Ionis Pharmaceuticals
$38.15 /

-0.09 (-0.24%)

GILD Gilead
$68.98 /

+0.43 (+0.63%)

GDRX GoodRx
$30.08 /

-0.91 (-2.94%)

CP Canadian Pacific
$79.99 /

+0.07 (+0.09%)

Conference/Events
Passage Bio to host research and development day » 09:20
05/17/21
05/17
09:20
05/17/21
09:20
PASG

Passage Bio

$15.49 /

-0.33 (-2.09%)

Research and Development…

Research and Development Day to be held on May 17 at 9:30 am. Webcast Link

ShowHide Related Items >><<
PASG Passage Bio
$15.49 /

-0.33 (-2.09%)

PASG Passage Bio
$15.49 /

-0.33 (-2.09%)

04/05/21 Morgan Stanley
Regenxbio AAV9 patent challenged by Passage Bio, says Morgan Stanley
03/08/21 Chardan
Passage Bio price target raised to $45 from $35 at Chardan
03/04/21 Citi
Citi remains buyer of Passage Bio into first clinical data
03/04/21 Goldman Sachs
Passage Bio upgraded to Buy from Neutral at Goldman Sachs
PASG Passage Bio
$15.49 /

-0.33 (-2.09%)

  • 22
    Jan
PASG Passage Bio
$15.49 /

-0.33 (-2.09%)

PASG Passage Bio
$15.49 /

-0.33 (-2.09%)

Hot Stocks
OrthoPediatrics continues Double Diamond Sponsorship for POSNA meeting » 09:20
05/17/21
05/17
09:20
05/17/21
09:20
KIDS

OrthoPediatrics

$55.88 /

-0.43 (-0.76%)

OrthoPediatrics has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
KIDS OrthoPediatrics
$55.88 /

-0.43 (-0.76%)

KIDS OrthoPediatrics
$55.88 /

-0.43 (-0.76%)

05/07/21 Truist
OrthoPediatrics price target raised to $72 from $64 at Truist
05/07/21 JMP Securities
OrthoPediatrics price target raised to $70 from $55 at JMP Securities
05/06/21 Piper Sandler
OrthoPediatrics price target raised to $70 from $62 at Piper Sandler
04/19/21 Truist
OrthoPediatrics price target raised to $64 from $54 at Truist
KIDS OrthoPediatrics
$55.88 /

-0.43 (-0.76%)

  • 18
    Jun
KIDS OrthoPediatrics
$55.88 /

-0.43 (-0.76%)

Earnings
Gracell reports Q1 EPS (5c), consensus (21c) » 08:06
05/17/21
05/17
08:06
05/17/21
08:06
GRCL

Gracell

$11.03 /

+1.27 (+13.02%)

"We are thrilled to…

"We are thrilled to have ushered in the new year as a public company following a successful initial public offering that was supported by top-tier institutional investors," commented Dr. William Cao, founder, Chairman, and CEO of Gracell. "We have made significant advancements during the first quarter regarding our pipeline of innovative autologous and allogeneic CAR-T cell therapies. Recently, we announced dosing the first patient in the Phase 1/2 registrational study of GC007g, an allogeneic CAR-T cell therapy derived from HLA-matched donors for the treatment of r/r B-ALL. At the AACR 2021 Annual Meeting last month, we presented follow-up data on our off-the-shelf stand-alone allogeneic CAR-T cell therapy GC027 for the treatment of r/r T-ALL. With a patient maintaining minimal residual disease negative complete remission through 16.8 months, we are very encouraged by the potential of GC027 in this hard-to-treat indication. We are pleased to announce that we are expanding our leadership team with Jenny Ni, Ph.D., M.D., as Chief Technology Officer. Dr. Ni brings extensive experience in developing CAR-T cell therapies, including having successfully lead process development at both Pfizer and Allogene Therapeutics. We look forward to her contributions, including leading our technical operations teams including Chemistry, Manufacturing and Control and manufacturing to ensure a smooth technology transfer to Lonza for our FasTCAR-enabled product candidate GC012F. We plan to build on the momentum achieved during the first quarter with several near-term catalysts expected during 2021. As we continue to ramp up clinical development efforts, we continue to expand our team in the U.S. and preparing to expand our GMP manufacturing facility in China. We also look forward to providing updates at the ASCO and EHA 2021 annual meetings on the FasTCAR-enabled BCMA/CD19 dual-targeting candidate GC012F for the treatment of r/r multiple myeloma, which has demonstrated fast, deep, and durable responses in a predominantly high-risk multiple myeloma patient population. We are excited to begin collaborating with Lonza to manufacture our FasTCAR-enabled product candidate GC012F as we work towards the U.S. IND filing in the first half of 2022. We believe the potential of our proprietary FasTCAR and TruUCAR platforms is vast, and we are working expeditiously to bring new product candidates into clinical development," Dr. Cao concluded.

ShowHide Related Items >><<
GRCL Gracell
$11.03 /

+1.27 (+13.02%)

GRCL Gracell
$11.03 /

+1.27 (+13.02%)

04/30/21 Piper Sandler
Gracell transferred with Overweight rating at Piper Sandler
02/03/21 Citi
Gracell initiated with a Buy at Citi
02/02/21 Jefferies
Gracell initiated with a Buy at Jefferies
02/02/21 Wells Fargo
Gracell initiated with an Overweight at Wells Fargo
  • 08
    Jan
GRCL Gracell
$11.03 /

+1.27 (+13.02%)

Hot Stocks
Cytokinetics announces presentation of data from GALACTIC-HF » 08:03
05/17/21
05/17
08:03
05/17/21
08:03
CYTK

Cytokinetics

$25.95 /

+0.75 (+2.98%)

Cytokinetics announced…

Cytokinetics announced that data from a secondary analysis of GALACTIC-HF assessing the effect of omecamtiv mecarbil on clinical outcomes in relationship to patient baseline ejection fraction were presented by John Teerlink, Professor of Medicine, University of California San Francisco, Director of Heart Failure, San Francisco Veterans Affairs Medical Center and Executive Committee Chair, GALACTIC-HF in a Late Breaking Clinical Trial session at the American College of Cardiology 70th Annual Scientific Session & Expo and were simultaneously published in the Journal of the American College of Cardiology.

ShowHide Related Items >><<
CYTK Cytokinetics
$25.95 /

+0.75 (+2.98%)

CYTK Cytokinetics
$25.95 /

+0.75 (+2.98%)

05/11/21 Mizuho
Cytokinetics price target raised to $36 from $26 at Mizuho
03/11/21 Wolfe Research
Cytokinetics initiated with an Outperform at Wolfe Research
02/18/21 Barclays
Cytokinetics initiated with an Overweight at Barclays
01/20/21 H.C. Wainwright
Cytokinetics price target raised to $41 from $22 at H.C. Wainwright
CYTK Cytokinetics
$25.95 /

+0.75 (+2.98%)

  • 17
    Jul
Friday
Hot Stocks
Veracyte announces data showing Percepta Genomic Atlas detects gene alterations » 12:46
05/14/21
05/14
12:46
05/14/21
12:46
VCYT

Veracyte

$36.81 /

+1.7 (+4.84%)

Veracyte announced new…

Veracyte announced new data demonstrating the ability of the Percepta Genomic Atlas to detect alterations that may inform lung cancer treatment decisions for patients from the same small biopsy that was used for diagnosis. Study findings presented today at the American Thoracic Society 2021 International Conference show that the test accurately detects known lung-cancer gene variants using small biopsy samples, which may help guide treatment with targeted therapies. For the analyses presented at the ATS Conference, researchers evaluated the feasibility of detecting National Comprehensive Cancer Network-recommended gene alterations with the Percepta Genomic Atlas, using samples from 25 patients obtained during initial bronchoscopy procedures. Results show that the in-development test accurately detected the gene variants in these samples with over 95% concordance to a reference next-generation sequencing assay.

ShowHide Related Items >><<
VCYT Veracyte
$36.81 /

+1.7 (+4.84%)

VCYT Veracyte
$36.81 /

+1.7 (+4.84%)

05/11/21 Needham
Veracyte price target lowered to $54 from $88 at Needham
05/11/21 SVB Leerink
Veracyte price target lowered to $65 from $75 at SVB Leerink
04/27/21 SVB Leerink
Veracyte price target lowered to $75 from $85 at SVB Leerink
02/18/21 Needham
Veracyte assumed with a Buy at Needham
VCYT Veracyte
$36.81 /

+1.7 (+4.84%)

  • 05
    Feb
  • 05
    Aug
On The Fly
Fly Intel: Pre-market Movers » 09:09
05/14/21
05/14
09:09
05/14/21
09:09
VVNT

Vivint Smart Home

$11.75 /

+0.6 (+5.38%)

, SNOW

Snowflake

$188.13 /

-3.12 (-1.63%)

, PLUG

Plug Power

$21.96 /

-0.27 (-1.21%)

, ITRM

Iterum Therapeutics

/

+

, FREE

Whole Earth Brands

$12.76 /

-0.31 (-2.37%)

, SLDB

Solid Biosciences

$4.43 /

-0.18 (-3.90%)

, DASH

DoorDash

$116.22 /

+3.24 (+2.87%)

, COIN

Coinbase

$265.00 /

-18.6 (-6.56%)

, BPTH

Bio-Path

$5.16 /

-0.23 (-4.27%)

, DIS

Disney

$178.11 /

+0.26 (+0.15%)

, CRMD

CorMedix

$7.61 /

-0.26 (-3.30%)

, PTE

PolarityTE

$1.21 /

-0.02 (-1.63%)

, MKGI

Monaker Group

$2.94 /

-0.01 (-0.34%)

Check out this morning's…

ShowHide Related Items >><<
VVNT Vivint Smart Home
$11.75 /

+0.6 (+5.38%)

SNOW Snowflake
$188.13 /

-3.12 (-1.63%)

SLDB Solid Biosciences
$4.43 /

-0.18 (-3.90%)

PTE PolarityTE
$1.21 /

-0.02 (-1.63%)

PLUG Plug Power
$21.96 /

-0.27 (-1.21%)

MKGI Monaker Group
$2.94 /

-0.01 (-0.34%)

ITRM Iterum Therapeutics
/

+

FREE Whole Earth Brands
$12.76 /

-0.31 (-2.37%)

DIS Disney
$178.11 /

+0.26 (+0.15%)

DASH DoorDash
$116.22 /

+3.24 (+2.87%)

CRMD CorMedix
$7.61 /

-0.26 (-3.30%)

COIN Coinbase
$265.00 /

-18.6 (-6.56%)

BPTH Bio-Path
$5.16 /

-0.23 (-4.27%)

VVNT Vivint Smart Home
$11.75 /

+0.6 (+5.38%)

05/14/21 Goldman Sachs
Vivint Smart Home upgraded to Buy from Neutral at Goldman Sachs
03/11/21 Deutsche Bank
Vivint upgraded to Buy on long-term opportunities at Deutsche Bank
03/11/21 Deutsche Bank
Vivint Smart Home upgraded to Buy from Hold at Deutsche Bank
02/25/21 Deutsche Bank
Vivint Smart Home price target lowered to $21 from $24 at Deutsche Bank
SNOW Snowflake
$188.13 /

-3.12 (-1.63%)

05/14/21 Goldman Sachs
Snowflake upgraded to Buy from Neutral at Goldman Sachs
05/13/21 Mizuho
Snowflake price target lowered to $300 from $350 at Mizuho
05/03/21 Needham
Snowflake initiated with a Hold at Needham
05/03/21 Needham
Snowflake initiated with a Hold at Needham
PLUG Plug Power
$21.96 /

-0.27 (-1.21%)

04/19/21 Evercore ISI
Plug Power initiated with an Outperform at Evercore ISI
04/19/21 Wells Fargo
Plug Power initiated with an Equal Weight at Wells Fargo
04/12/21 Morgan Stanley
Plug Power resumed at Equal Weight from Overweight at Morgan Stanley
04/12/21 Morgan Stanley
Plug Power downgraded to Equal Weight from Overweight at Morgan Stanley
ITRM Iterum Therapeutics
/

+

03/15/21 H.C. Wainwright
Iterum Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
12/24/20 H.C. Wainwright
Iterum CSO resignation 'somewhat troubling,' says H.C. Wainwright
06/16/20 H.C. Wainwright
Iterum Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
06/02/20 RBC Capital
Iterum Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
FREE Whole Earth Brands
$12.76 /

-0.31 (-2.37%)

02/22/21 Lake Street
Whole Earth Brands initiated with a Buy at Lake Street
02/12/21 Jefferies
Whole Earth Brands initiated with a Buy at Jefferies
01/28/21
Fly Intel: Top five analyst initiations
01/28/21 Roth Capital
Whole Earth Brands initiated with a Buy at Roth Capital
SLDB Solid Biosciences
$4.43 /

-0.18 (-3.90%)

03/16/21 Chardan
Solid Biosciences price target raised to $20 from $12.50 at Chardan
03/16/21
Fly Intel: Top five analyst upgrades
03/16/21 SVB Leerink
Solid Biosciences upgraded to Outperform at SVB Leerink
03/16/21 SVB Leerink
Solid Biosciences upgraded to Outperform from Market Perform at SVB Leerink
DASH DoorDash
$116.22 /

+3.24 (+2.87%)

05/14/21 Wells Fargo
DoorDash upgraded to Overweight from Equal Weight at Wells Fargo
05/14/21 Wells Fargo
DoorDash upgraded to Overweight from Equal Weight at Wells Fargo
05/14/21 Truist
DoorDash upgraded to Buy from Hold at Truist
05/14/21 Truist
DoorDash upgraded to Buy from Hold at Truist
COIN Coinbase
$265.00 /

-18.6 (-6.56%)

05/14/21 Mizuho
Mizuho expects 'muted' stock reaction to 'strong' Coinbase results
05/14/21 Piper Sandler
Coinbase initiated with an Overweight at Piper Sandler
05/13/21 BTIG
BTIG sees Binance news as 'net positive' for Coinbase
05/13/21
Fly Intel: Top five analyst initiations
BPTH Bio-Path
$5.16 /

-0.23 (-4.27%)

04/06/21 H.C. Wainwright
Bio-Path price target raised to $12 from $10 at H.C. Wainwright
04/05/21 Roth Capital
Bio-Path triple regimen data 'highly favorable,' says Roth Capital
03/11/21 Roth Capital
Bio-Path Holdings initiated with a Buy at Roth Capital
11/16/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $10 from $12 at H.C. Wainwright
DIS Disney
$178.11 /

+0.26 (+0.15%)

05/14/21 Evercore ISI
Evercore doesn't see much in Disney Q2 report to materially change view
05/14/21 Morgan Stanley
Morgan Stanley 'not surprised' by Disney+ sub growth or commentary
05/14/21 Goldman Sachs
Disney price target lowered to $215 from $225 at Goldman Sachs
05/14/21 Citi
Disney shares to trade down on moderated sub outlook, says Citi
CRMD CorMedix
$7.61 /

-0.26 (-3.30%)

04/14/21 JMP Securities
JMP 'confident' CorMedix has clear CRL resolution path with FDA
03/31/21 Truist
CorMedix price target lowered to $27 from $30 at Truist
03/02/21 B. Riley
CorMedix price target lowered to $13.50 from $25 at B. Riley Securities
02/17/21 Needham
CorMedix initiated with a Buy at Needham
PTE PolarityTE
$1.21 /

-0.02 (-1.63%)

11/19/20 Cantor Fitzgerald
PolarityTE patent status change removes key overhang, says Cantor Fitzgerald
MKGI Monaker Group
$2.94 /

-0.01 (-0.34%)

VVNT Vivint Smart Home
$11.75 /

+0.6 (+5.38%)

SNOW Snowflake
$188.13 /

-3.12 (-1.63%)

SLDB Solid Biosciences
$4.43 /

-0.18 (-3.90%)

PTE PolarityTE
$1.21 /

-0.02 (-1.63%)

PLUG Plug Power
$21.96 /

-0.27 (-1.21%)

ITRM Iterum Therapeutics
/

+

FREE Whole Earth Brands
$12.76 /

-0.31 (-2.37%)

DIS Disney
$178.11 /

+0.26 (+0.15%)

DASH DoorDash
$116.22 /

+3.24 (+2.87%)

CRMD CorMedix
$7.61 /

-0.26 (-3.30%)

COIN Coinbase
$265.00 /

-18.6 (-6.56%)

BPTH Bio-Path
$5.16 /

-0.23 (-4.27%)

  • 14
    May
  • 14
    Apr
  • 19
    Mar
  • 16
    Mar
  • 16
    Feb
  • 27
    Jan
  • 29
    Dec
  • 09
    Dec
  • 17
    Nov
  • 16
    Sep
  • 12
    Aug
  • 28
    Jul
PLUG Plug Power
$21.96 /

-0.27 (-1.21%)

DIS Disney
$178.11 /

+0.26 (+0.15%)

DASH DoorDash
$116.22 /

+3.24 (+2.87%)

COIN Coinbase
$265.00 /

-18.6 (-6.56%)

VVNT Vivint Smart Home
$11.75 /

+0.6 (+5.38%)

SNOW Snowflake
$188.13 /

-3.12 (-1.63%)

SLDB Solid Biosciences
$4.43 /

-0.18 (-3.90%)

PTE PolarityTE
$1.21 /

-0.02 (-1.63%)

PLUG Plug Power
$21.96 /

-0.27 (-1.21%)

ITRM Iterum Therapeutics
/

+

DIS Disney
$178.11 /

+0.26 (+0.15%)

DASH DoorDash
$116.22 /

+3.24 (+2.87%)

COIN Coinbase
$265.00 /

-18.6 (-6.56%)

SNOW Snowflake
$188.13 /

-3.12 (-1.63%)

PTE PolarityTE
$1.21 /

-0.02 (-1.63%)

PLUG Plug Power
$21.96 /

-0.27 (-1.21%)

DIS Disney
$178.11 /

+0.26 (+0.15%)

DASH DoorDash
$116.22 /

+3.24 (+2.87%)

COIN Coinbase
$265.00 /

-18.6 (-6.56%)

Recommendations
TCR2 Therapeutics price target lowered to $45 from $57 at Wedbush » 07:27
05/14/21
05/14
07:27
05/14/21
07:27
TCRR

TCR2 Therapeutics

$19.05 /

-0.31 (-1.60%)

Wedbush analyst David…

Wedbush analyst David Nierengarten lowered the firm's price target on TCR2 Therapeutics to $45 from $57 and keeps an Outperform rating on the shares. The company reaffirmed that it is on track todetermine a recommended Phase 2 dose of gavo-cel for treatment-refractory mesothelin-expressing solid tumors and expects to initiate its Phase 1/2 expansion trial this year, Nierengarten tells investors in a research note. The analyst expects continued updates from treated patients over the rest of the year.

ShowHide Related Items >><<
TCRR TCR2 Therapeutics
$19.05 /

-0.31 (-1.60%)

TCRR TCR2 Therapeutics
$19.05 /

-0.31 (-1.60%)

03/12/21 Mizuho
TCR2 Therapeutics price target lowered to $51 from $58 at Mizuho
03/11/21 BMO Capital
TCR2 Therapeutics price target lowered to $56 from $65 at BMO Capital
03/11/21 Piper Sandler
TCR2 Therapeutics price target raised to $55 from $45 at Piper Sandler
12/22/20 Mizuho
Autolus, Arcus among top 2021 oncology picks at Mizuho
TCRR TCR2 Therapeutics
$19.05 /

-0.31 (-1.60%)

  • 20
    Jan
  • 29
    Jul
Earnings
Iterum Therapeutics reports Q1 adjusted EPS (5c), consensus (7c) » 07:05
05/14/21
05/14
07:05
05/14/21
07:05
ITRM

Iterum Therapeutics

/

+

As of March 31, 2021,…

As of March 31, 2021, Iterum had cash, cash equivalents and short-term investments of $100.5M. Based on its current operating plan, Iterum expects that its current cash, cash equivalents and short-term investments will be sufficient to fund its operations into the first half of 2023. "We continue to prepare for a U.S. Food and Drug Administration advisory committee meeting and look forward to clarity from the FDA on timing. In the meantime, the FDA continues its review of our new drug application for oral sulopenem for the treatment of uncomplicated urinary tract infections in patients with a quinolone non-susceptible organism and has not advised us of any change to the current PDUFA goal date of July 25, 2021," said Corey Fishman, CEO. "With an FDA decision on oral sulopenem expected in the second half of 2021 and a strong cash position, we are preparing for a launch of oral sulopenem into the community in the fourth quarter of 2021, if approved."

ShowHide Related Items >><<
ITRM Iterum Therapeutics
/

+

ITRM Iterum Therapeutics
/

+

03/15/21 H.C. Wainwright
Iterum Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
12/24/20 H.C. Wainwright
Iterum CSO resignation 'somewhat troubling,' says H.C. Wainwright
06/16/20 H.C. Wainwright
Iterum Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
06/02/20 RBC Capital
Iterum Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
ITRM Iterum Therapeutics
/

+

ITRM Iterum Therapeutics
/

+

Conference/Events
Morgan Stanley to hold a virtual conference » 04:55
05/14/21
05/14
04:55
05/14/21
04:55
GRCL

Gracell

$9.76 /

-1.015 (-9.42%)

, HOOK

Hookipa Pharma

$16.91 /

+0.16 (+0.96%)

, HCM

Hutchison China MediTech

$25.46 /

+1.47 (+6.13%)

Asia Healthcare Virtual…

Asia Healthcare Virtual Conference 2021 will be held on May 13-14.

ShowHide Related Items >><<
HOOK Hookipa Pharma
$16.91 /

+0.16 (+0.96%)

HCM Hutchison China MediTech
$25.46 /

+1.47 (+6.13%)

GRCL Gracell
$9.76 /

-1.015 (-9.42%)

GRCL Gracell
$9.76 /

-1.015 (-9.42%)

04/30/21 Piper Sandler
Gracell transferred with Overweight rating at Piper Sandler
02/03/21 Citi
Gracell initiated with a Buy at Citi
02/02/21 Jefferies
Gracell initiated with a Buy at Jefferies
02/02/21 Wells Fargo
Gracell initiated with an Overweight at Wells Fargo
HOOK Hookipa Pharma
$16.91 /

+0.16 (+0.96%)

04/08/21 Morgan Stanley
Hookipa Pharma initiated with an Overweight at Morgan Stanley
11/30/20 JMP Securities
Hookipa Pharma price target raised to $25 from $19 at JMP Securities
11/03/20
Fly Intel: Top five analyst initiations
11/03/20 Truist
Hookipa Pharma initiated with a Buy at Truist
HCM Hutchison China MediTech
$25.46 /

+1.47 (+6.13%)

10/02/20 Deutsche Bank
Hutchison China MediTech initiated with a Buy at Deutsche Bank
HOOK Hookipa Pharma
$16.91 /

+0.16 (+0.96%)

HCM Hutchison China MediTech
$25.46 /

+1.47 (+6.13%)

  • 08
    Jan
  • 09
    Dec
HOOK Hookipa Pharma
$16.91 /

+0.16 (+0.96%)

GRCL Gracell
$9.76 /

-1.015 (-9.42%)

HCM Hutchison China MediTech
$25.46 /

+1.47 (+6.13%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.